Polyrizon (PLRZ) said Wednesday it has entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a European-based GMP-certified manufacturer, to supply clinical trial material for its PL-14 allergy blocker study expected to begin in 2025.
The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker, the company said.
Polyrizon said the manufacturing site for the clinical trial material will meet US and European regulatory standards and provide high-quality development support for the 2025 trial.
Polyrizon shares were 160% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments